Necrotizing Enterocolitis (NEC) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Necrotizing enterocolitis (NEC) is a disease seen primarily in preterm infants. In some ways, NEC is a byproduct of the successes experienced in neonatology wherein babies of low gestational age who would not have survived 30–40 years ago are now surviving. NEC has emerged as one of the most destructive diseases occurring in neonatal intensive care. In addition to extremely high morbidity and mortality and high costs, long-term complications include strictures and adhesions of the intestine, cholestasis, short bowel syndrome, failure to thrive, and neurodevelopmental delay. Unfortunately, not much progress has been made in its treatment or prevention. Barrier function, circulatory regulation, motility, digestion, absorption, and immune defenses are immature in preterm infants. In addition, the balance between effector and tolerizing immune response may not be fully developed. Classic NEC appears to be related to excessive inflammatory responses, with elevated serum cytokines and chemokines, especially IL-8. Other high factors that could potentially be used as biomarkers for NEC include claudin 3 (a tight junction protein), intestinal fatty acid-binding protein, which is produced by the epithelial cells, and fecal calprotectin, which is the product of inflammatory cells.

Necrotizing enterocolitis (NEC) may affect up to 5% of low-birth weight infants, more common among infants with weight <1,500 gm at birth. Also, ~7 to 14% of Necrotizing enterocolitis (NEC) cases in full-term birth.

 

The competitive landscape of Necrotizing Enterocolitis (NEC) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Necrotizing Enterocolitis (NEC) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Necrotizing Enterocolitis (NEC) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Necrotizing Enterocolitis (NEC) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          ST266  Noveome Biotherapeutics, Inc    Phase 1

2          IBP-9414          Infant Bacterial Therapeutics      Phase 3

3          Sulfur hexafluoride lipid-type A microspheres      Bracco Diagnostics, Inc Phase 3

4          Supplement: Lactobacillus reuteri           BioGaia AB       Phase 2

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more